- Visibility 17 Views
- Downloads 8 Downloads
- Permissions
- DOI 10.18231/j.ijpo.12466.1759818827
-
CrossMark
Trastuzumab deruxtecan in breast cancer: Current status and future directions
- Author Details:
-
Praloy Basu *
Praloy Basu *
Breast cancer is the most prevalent malignancy in women globally, with HER2-positive disease constituting approximately 15–20% of cases. The advent of HER2-targeted therapies has significantly improved outcomes; however, therapeutic resistance in metastatic settings remains a challenge. Trastuzumab deruxtecan (T-DXd) is a HER2-directed antibody–drug conjugate (ADC) made up of a humanized anti-HER2 monoclonal antibody attached to a topoisomerase I inhibitor payload through a cleavable linker. A high drug-to-antibody ratio and a bystander effect has resulted in a significant efficacy in HER2-positive metastatic breast cancer (mBC), particularly those who have received multiple lines of therapy, as shown in DESTINY-Breast01 and DESTINY-Breast03 trials. Furthermore, the DESTINY-Breast04 study established T-DXd as the first effective therapy for HER2-low mBC. This led to a redefinition of the categories of HER2 expression. T-DXd is also under investigation in early-stage disease, with encouraging results in neoadjuvant and adjuvant settings. While generally well tolerated, interstitial lung disease (ILD) remains a notable risk, necessitating vigilant monitoring. Patient-reported outcomes indicate maintained or improved quality of life with T-DXd. Ongoing research is focused on expanding its role through combination strategies, exploring its use in HER2-ultralow tumors, and identifying predictive biomarkers such as HER2 mRNA levels and topoisomerase I expression. Additionally, T-DXd is being evaluated in other HER2-expressing malignancies including lung, gastric, and colorectal cancers. Overall, T-DXd represents a paradigm shift in HER2-targeted therapy, offering clinical benefit across a broader spectrum of breast cancer subtypes and treatment settings.
References
- Modi S, Saura C, Yamashita T, Park YH, Kim S-B, Tamura K, et al.; DESTINY-Breast01 Investigators. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2020;382(7):610–21. https://doi.org/10.1056/NEJMoa1914510
[Google Scholar] - Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N, et al. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. Clin Cancer Res. 2016;22(20):5097–108. https://doi.org/10.1158/1078-0432.CCR-
[Google Scholar] 15-2822. - Nakada T, Sugihara K, Jikoh T, Abe Y, Agatsuma T. The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy. Chem Pharm Bull (Tokyo). 2019;67(3):173–85. https://doi.org/10.1248/cpb.c18-00744
[Google Scholar] - Modi S, Saura C, Yamashita T, Park YH, Kim S-B, Tamura K, et al.; DESTINY-Breast01 Investigators. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2020;382(7):610–21. https://doi.org/10.1056/NEJMoa1914510
[Google Scholar] - Cortés J, Kim S-B, Chung W-P, Im S-A, Park YH, Hegg R, et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med. 2022;386(12):1143–54. https://doi.org/10.1056/NEJMoa2115022
[Google Scholar] - Saura C, Modi S, Krop I, Park YH, Kim SB, Tamura K, et al. Trastuzumab deruxtecan in previously treated patients with HER2- positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01). Ann Oncol. 2024;35(3):302–7. https://doi.org/10.1016/j.annonc.2023.12.001
[Google Scholar] - Harbeck N, Ciruelos E, Jerusalem G, Müller V, Niikura N, Viale G, et al. Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial. Nat Med. 2024;30(12):3717–27. https://doi.org/10.1038/s41591-024-03261-
[Google Scholar] - Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al.; DESTINY-Breast04 Trial Investigators. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022;387(1):9–20. https://doi.org/10.1056/NEJMoa2203690
[Google Scholar] - Franchina M, Pizzimenti C, Fiorentino V, Martini M, Ricciardi GRR, Silvestris N, et al. Low and Ultra-Low HER2 in Human 234 Basu / Indian Journal of Pathology and Oncology 2025;12(3):230–234 Breast Cancer: An Effort to Define New Neoplastic Subtypes. Int J Mol Sci. 2023;24(16):12795. https://doi.org/10.3390/ijms241612795
[Google Scholar] - Harbeck N, Boileau JF, Modi S, Kelly CM, Ohno S, Wu J, et al. Abstract OT1-12-04: A phase 3, open-label trial of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy or T-DXd followed by THP compared with ddAC-THP in patients with high-risk HER2-positive early-stage breast cancer (DESTINY-Breast11). Cancer Res. 2022;82(4 Suppl):OT1-12-04. https://doi.org/10.1158/1538-7445.SABCS21-OT1-12-04
[Google Scholar] - Geyer CE, Untch M, Prat A, Rastogi P, Niikura N, Mathias E, et al. Abstract OT-03-01: Trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2- positive, residual invasive early breast cancer after neoadjuvant therapy: A randomized, phase 3 trial (DESTINY-Breast05). Cancer Res. 2021;81(4 Suppl):OT-03-01. https://doi.org/10.1158/1538-
[Google Scholar] - SABCS20-OT-03-01.
- Swain SM, Nishino M, Lancaster LH, Li BT, Nicholson AG, Bartholmai B, et al. Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis—Focus on proactive monitoring, diagnosis, and management. Cancer Treat Rev. 2022;106:102378. https://doi.org/10.1016/j.ctrv.2022.102378
[Google Scholar] - Dent SF, Morse A, Burnette S, Guha A, Moore H. Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer. Curr Oncol Rep . 2021;23(11):128. https://doi.org/10.1007/s11912-021-01114-x
[Google Scholar] - Emens LA. Breast Cancer Immunotherapy: Facts and Hopes. Clin Cancer Res. 2018;24(3):511–20. https://doi.org/10.1158/1078-
[Google Scholar] - CCR-16-3001.
- Dent RA, Curigliano G, Hu X, Yonemori K, Barrios CH, Wildiers H, et al. Exploratory biomarker analysis of trastuzumab deruxtecan (T-DXd) vs physician's choice of chemotherapy (TPC) in HER2- low/ultralow, hormone receptor-positive (HR+) metastatic breast cancer (mBC) in DESTINY-Breast06 (DB-06). J Clin Oncol. 2025;43(16 Suppl):1013-1013. https://doi.org/10.1200/JCO.2025.43.16_suppl.1013
[Google Scholar]